Cerenome expects Q3 CNSide gross billings of $1.55 million

PUBT · 1d ago
Cerenome expects Q3 CNSide gross billings of $1.55 million
  • Cerenome projected Q3 2026 CNSide gross billings of USD 1.55 million from 222 tests billed at list prices.
  • Annualized gross billing run rate expected at about USD 10 million to USD 12 million in Q4 2026, based on list pricing.
  • Total test volume targeted at an annualized run rate of 1,250 tests in Q4 2026, supporting the billing outlook.
  • Initial cash collections anticipated in Q4 2026, with Medicare pricing for PLA code 0640U targeted to take effect Jan. 1, 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cerenome Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609300730PRIMZONEFULLFEED9836632) on September 30, 2026, and is solely responsible for the information contained therein.